Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
August 1, 2017 4:05 PM EDTCommercial & Financial Highlights
Revenue of $35.6 million in second quarter 2017, an increase of 80 percent from second quarter 2016 2017 revenue guidance increased by $20 million, to $145-155 millionGAAP net income of $0.10 per share, compared to $0.01 per share in second quarter 2016Non-GAAP net income of $0.13 per share, compared to $0.03 per share in second quarter 2016Final payment made in July 2017 on capped royalty financing obligationÂClinical Highlights
Enrollment continues in Phase 2, open-label trial of CORT125134... More